FDA grants orphan designation to Fragile X syndrome therapeutic
Spinogenix’s SPG601 Earns Orphan Drug Designation for Fragile X Syndrome
Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X Syndrome
Press Release Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X Syndrome Receiving Orphan Drug Designation for SPG601 emphasizes the pressing demand for novel therapies for individuals living with Fragile X Syndrome LOS ANGELES, Calif., May 20, 2024 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics […]
FDA clears Phase 2 trial of oral SPG601 in men with fragile X
FDA clears investigational new drug application for Fragile X treatment
Two major breakthroughs in Fragile X Syndrome treatments
Spinogenix’s Investigational New Drug Application for Novel Treatment for Fragile X Syndrome Cleared to Begin Phase II Trial
Spinogenix Announces U.S. FDA Approval of its Investigational New DrugApplication for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome
Press Release Spinogenix Announces U.S. FDA Approval of its Investigational New Drug Application for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome SPG601 is a once-a-day pill that works by restoring synaptic function to address core symptoms of Fragile X Syndrome LOS ANGELES, Calif., April 15, 2024 — Spinogenix, Inc., a clinical-stage […]
